

5th Annual Diabetes Conference
"Innovated steps changing the journey of diabetes"
 2nd-4th February 2009
 London, UK

Target Audience

- Pharmaceutical Organisations
- Generic pharmaceutical companies
- Government- Department of Health
- Non-profit Organisations/Association
- Academics
- Consultants

VPs, Directors, Heads and Managers of:

- Endocrinology & Metabolism
- Cardiovascular & Metabolism Diseases
- Diabetes & Obesity, Clinical Developments
- Advanced Diabetes Systems
- Drug Delivery
- Product development
- Marketing/Sales
- Pricing
- Product Management
- Regulator Organisers
- Clinical Pharmacology
- Projected Management
- Scientific Affairs
- Healthcare Professionals
- Licensing and Partnering

Day One
Pre-conference Workshop
Monday 2nd February 2009

Insights into Beta Recovery in newly diagnosed T1 diabetic patients and T2 diabetic patients

Workshop Leader-
Dr Peter Damsbo
 Managing Director
DAMSBO
 life science resources

Day Two
Tuesday 3rd February 2009

09:00 – Registration and refreshments

09:30 – Opening address from Morning chair

Dr Costanza Emanuelli
 BHF Reader at Bristol University
University of Bristol

09:40 – The story with Leptin-Aiding in T1 Diabetes and obesity

- Insulin .V. Leptin- Who's the leading contender?
- Leptin Responsiveness in Diet-Induced Obesity-
- The improved knowledge of Leptin, since being discovered in 1994
- Leptin receptors and their partnership with T cells activity in immune system

10:20-Amphibian skin secretions, a new approach for the treatment of Type 2 Diabetes

- The innovation and determination behind the research of additional findings
- New class of medicines called incretin mimetics which mimic natural substances.
- The next steps- More research is needed

Dr Yasser Abdel Wahab
 Senior Lecturer in Biomedical Scientist
Ulster University

11:00 – Morning refreshments and net working opportunities

11:20- Role of the p75 neurotrophin receptor (p75NTR) in microvascular pathology

- These recent developments provide new insights into the functions of this enigmatic receptor
- Investigations into the development of new drugs to resist the effects p75NTR
- Beneficial effects of new drugs on one of the most devastating and life threatening complications associated with diabetes

Dr Costanza Emanuelli
 BHF Reader at Bristol University
University of Bristol

12:10- Update on Diabetology's oral insulin product Capsulin®

- Oral insulin has many potential advantages over other forms of Insulin delivery
- Capsulin promises to be an exciting candidate for the improved treatment of the millions of sufferers of diabetes around the world.

Dr Roger New
Chief Scientist
Diabetology

12:50- The use of Statins for all diabetic patients

- Reducing the risk of hearts attacks and strokes in diabetic patients
- Future discoveries how statins will have an effect of Diabetes as a worldwide disease
- The benefits of Satins being prescribed to local authorities and the cost effectiveness as a whole

Dr Dunger
Professor of Paediatrics
University of Cambridge

13:30- Networking Lunch

14:50- Online support communities - the positives and pitfalls of virtual diabetes communities

Case Study

Daniel Crockett
Managing Editor
Diabetes.co.uk

15:30 – Afternoon refreshments

15:50 – Pricing and reimbursement for diabetes drugs in Europe

- The latest trends in pricing and reimbursement of Diabetes products
- Analysing the competitive market- What is driving the competitive edge within the diabetes market
- Value for money- What the consumers expect
- Understand how the diabetes pricing and reimbursement environment may evolve over the next five years

Martin Walter
Partner
Simon-Kucher & Partners

16:30- The human placenta in gestational diabetes mellitus

- Comparing the cell profiles from normal and diseased placentas
- Evidence into that disease such as diabetes can start from the placenta
- Adipokines are key players in the regulation of insulin action between placenta and adipose tissue
- Intensive research into insulin secretagogues

Invited: Prof. David Simmons
Managing Director
Wolfson Diabetes and Endocrinology Clinic

17:10 – Closing remarks from the chair

17:20 – Networking drinks

Day Three
Wednesday 4th February 2009

09:00 – Registration and refreshments

09.30 – Opening address from the chair

09:40- Using stem cell transplants to treat type I Diabetes

Invited: Dr Richard Burt
Associate Professor, Division of Immunotherapy
North Western University

10:20- Opportunities and challenges for the development of pharmacological therapies for diabetes treatment

Professor Michael Cawthorne
Professional Research Fellow & Director of Metabolic Research
Clare Laboratory- The University of Buckinghamshire

11:00 – Morning refreshments and net working opportunities

11:20-Pharmacological strategies for targeting the endocannabinoid system

- Exploring and validating Cannabinoid receptor, CB₁ and CB₂, in clinical trials
- New Targets for obesity pharmacotherapy
- Phase III of CP-945598- CB-1 receptor for the treatment of obesity

Dr Andrew G. Swick
Director of Cardiovascular & Metabolic Disease
Pfizer Global Research & Development

12:00-Current and future positioning of key competitors in the type 2 diabetes market

- Factors driving the shift in standard of care and innovation in diabetes.
- Emerging therapies—which ones best address today's needs?
- The future of DPP-IV inhibitors for type 2 diabetes.

Donny Wong
Principal Analyst, Metabolic and cardiovascular Disorders
Decisions Resources

12:40- Diabetic retinopathy and new therapeutic approaches

Case Study

James Bainbridge
Consultant Ophthalmologist
Moorfields Eye Hospital

13:40 – Networking lunch

14:40- Presentation to be confirmed

15:00- Afternoon refreshments and net working opportunities

15:20- Developing business opportunities through improved relationships with healthcare providers

- Understanding the market needs for treatment of obesity and the relationship with Type 2 Diabetes
- Demonstrating the economic and humanistic benefits of future diabetes therapies
- Impact of emerging information/data in relation to new findings

Senior Representative

Senior Posting

IMS Health

16:00- Chair's closing remarks

16:30 - End of conference

Draft